An assay to monitor HIV-1 protease activity for the identification of novel inhibitors in T-cells

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Hilton, Brett J ^a   Wolkowicz, Roland ^a  

^a SAN DIEGO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; DARUNAVIR; ENHANCED GREEN FLUORESCENT PROTEIN; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TIPRANAVIR; TRANSCRIPTION FACTOR GAL4; GREEN FLUORESCENT PROTEIN; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CELL ASSAY; CELL LINE; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME KINETICS; EXPRESSION VECTOR; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPORTER GENE; SENSITIVITY ANALYSIS; T LYMPHOCYTE; VIRUS GENOME; VIRUS PARTICLE; VIRUS STRAIN; CELL CYCLE; ENZYMOLOGY; FLOW CYTOMETRY; GENETICS; HYDROLYSIS; METABOLISM;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CELL CYCLE; CELL LINE; FLOW CYTOMETRY; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HIV PROTEASE; HUMANS; HYDROLYSIS; T-LYMPHOCYTES;

EID: 77956216235     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010940     Document Type: Article

References (36)

1. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, et al. (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (New York, NY 220(4599): 868-871.
2. Martin Stoltzfus C (2009) Chapter 1. Regulation of HIV-1 alternative RNA splicing and its role in virus replication. Advances in virus research 74: 1-40.
3. Bolinger C, Boris-Lawrie K (2009) Mechanisms employed by retroviruses to exploit host factors for translational control of a complicated proteome. Retrovirology 6: 8.
4. Colvin R, Haas G (1995) Protease inhibitor update. Common Factor (no 10): 15.
5. Hammer SM, Eron JJ, Jr, Reiss P, Schooley RT, Thompson MA, et al. (2008) Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. Jama 300(5): 555-570.
6. Speck RR, Flexner C, Tian CJ, Yu XF (2000) Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors. Antimicrobial agents and chemotherapy 44(5): 1397-1403.
7. Pettit SC, Lindquist JN, Kaplan AH, Swanstrom R (2005) Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology 2: 66.
8. Vogt VM (1996) Proteolytic processing and particle maturation. Curr Top Microbiol Immunol 214: 95-131.
9. Wiegers K, Rutter G, Kottler H, Tessmer U, Hohenberg H, et al. (1998) Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. Journal of virology 72(4): 2846-2854.
10. McCune JM, Rabin LB, Feinberg MB, Lieberman M, Kosek JC, et al. (1988) Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 53(1): 55-67.
11. Vollenweider F, Benjannet S, Decroly E, Savaria D, Lazure C, et al. (1996) Comparative cellular processing of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp160 by the mammalian subtilisin/kexin-like convertases. The Biochemical journal 314(Pt 2): 521-532.
12. Loeb DD, Swanstrom R, Everitt L, Manchester M, Stamper SE, et al. (1989) Complete mutagenesis of the HIV-1 protease. Nature 340(6232): 397-400.
13. Ishima R, Torchia DA, Louis JM (2007) Mutational and structural studies aimed at characterizing the monomer of HIV-1 protease and its precursor. J Biol Chem 282(23): 17190-17199.
14. Erickson J, Neidhart DJ, VanDrie J, Kempf DJ, Wang XC, et al. (1990) Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science (New York, NY 249(4968): 527-533.
15. Seelmeier S, Schmidt H, Turk V, von der Helm K (1988) Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proceedings of the National Academy of Sciences of the United States of America 85(18): 6612-6616.
16. von der Helm K, Gurtler L, Eberle J, Deinhardt F (1989) Inhibition of HIV replication in cell culture by the specific aspartic protease inhibitor pepstatin A. FEBS Lett 247(2): 349-352.
17. Toth MV, Marshall GR (1990) A simple, continuous fluorometric assay for HIV protease. Int J Pept Protein Res 36(6): 544-550.
18. Molla A, Vasavanonda S, Kumar G, Sham HL, Johnson M, et al. (1998) Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 250(2): 255-262.
19. Matayoshi ED, Wang GT, Krafft GA, Erickson J (1990) Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science (New York, NY 247(4945): 954-958.
20. Krausslich HG, Ingraham RH, Skoog MT, Wimmer E, Pallai PV, et al. (1989) Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides. Proceedings of the National Academy of Sciences of the United States of America 86(3): 807-811.
21. Cheng TJ, Brik A, Wong CH, Kan CC (2004) Model system for highthroughput screening of novel human immunodeficiency virus protease inhibitors in Escherichia coli. Antimicrobial agents and chemotherapy 48(7): 2437-2447.
22. Murray MG, Hung W, Sadowski I, Das Mahapatra B (1993) Inactivation of a yeast transactivator by the fused HIV-1 proteinase: a simple assay for inhibitors of the viral enzyme activity. Gene 134(1): 123-128.
23. Lindsten K, Uhlikova T, Konvalinka J, Masucci MG, Dantuma NP (2001) Cellbased fluorescence assay for human immunodeficiency virus type 1 protease activity. Antimicrobial agents and chemotherapy 45(9): 2616-2622.
24. Fuse T, Watanabe K, Kitazato K, Kobayashi N (2006) Establishment of a new cell line inducibly expressing HIV-1 protease for performing safe and highly sensitive screening of HIV protease inhibitors. Microbes Infect 8(7): 1783-1789.
25. Hu K, Clement JF, Abrahamyan L, Strebel K, Bouvier M, et al. (2005) A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer. J Virol Methods 128(1-2): 93-103.
26. Fischer JA, Giniger E, Maniatis T, Ptashne M (1988) GAL4 activates transcription in Drosophila. Nature 332(6167): 853-856.
27. Johnston SA, Zavortink MJ, Debouck C, Hopper JE (1986) Functional domains of the yeast regulatory protein GAL4. Proceedings of the National Academy of Sciences of the United States of America 83(17): 6553-6557.
28. Dasmahapatra B, DiDomenico B, Dwyer S, Ma J, Sadowski I, et al. (1992) A genetic system for studying the activity of a proteolytic enzyme. Proceedings of the National Academy of Sciences of the United States of America 89(9): 4159-4162.
29. Wolkowicz R, Nolan GP, Curran MA (2004) Lentiviral vectors for the delivery of DNA into mammalian cells. Methods in molecular biology (Clifton, NJ 246: 391-411.
30. Nascimbeni M, Lamotte C, Peytavin G, Farinotti R, Clavel F (1999) Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture. Antimicrobial agents and chemotherapy 43(11): 2629-2634.
31. Gong YF, Robinson BS, Rose RE, Deminie C, Spicer TP, et al. (2000) In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrobial agents and chemotherapy 44(9): 2319-2326.
32. Sadler BM, Stein DS (2002) Clinical pharmacology and pharmacokinetics of amprenavir. The Annals of pharmacotherapy 36(1): 102-118.
33. Baxter JD, Schapiro JM, Boucher CA, Kohlbrenner VM, Hall DB, et al. (2006) Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. Journal of virology 80(21): 10794-10801.
34. Matsuda Z, Iga M, Miyauchi K, Komano J, Morishita K, et al. (2007) In vitro translation to study HIV protease activity. Methods in molecular biology (Clifton, NJ 375: 135-149.
35. Mouland AJ, Coady M, Yao XJ, Cohen EA (2002) Hypophosphorylation of poly(A) polymerase and increased polyadenylation activity are associated with human immunodeficiency virus type 1 Vpr expression. Virology 292(2): 321-330.
36. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, et al. (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (New York, NY 272(5259): 263-267.